Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages
18 months to 18 years, who have severe, chronic ITP. Eligible patients with either primary or
secondary ITP are treated with rituximab once a week for 4 doses, and then followed for up to
one year. Response is defined as having a platelet count greater than or equal to 50,000/mL
on four consecutive weekly measures beginning anytime in weeks 9 - 12.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Neufeld, Ellis J, MD, PhD
Collaborators:
Biogen Genentech, Inc. Glaser Pediatric Research Network Terrana ITP Research Fund